Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25821996 | 0.90 | CACNA1B (0.47) | CACNA1BKDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL3704874 | 0.89 | CACNA1B (0.47) | CACNA1BKDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL19291558 | 0.88 | CACNA1B (0.47) | CACNA1BKDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL29818806 | 0.88 | CACNA1B (0.47) | CACNA1BKDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL2205412 | 0.88 | CACNA1B (0.47) | CACNA1BKDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL25823428 | 0.87 | L3MBTL1 (0.49) | KDM4EALDH1A1SMN1; SMN2NSD2LMNA | |
| SCHEMBL4568896 | 0.87 | CACNA1B (0.54) | CACNA1BKDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL2204508 | 0.84 | CACNA1B (0.43) | CACNA1BKDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL25820408 | 0.83 | KDM4E (0.58) | KDM4EALDH1A1SMN1; SMN2NSD2LMNA | |
| SCHEMBL25818192 | 0.79 | KDM4E (0.46) | KDM4EALDH1A1SMN1; SMN2NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | CACNA1B 4210/4885KDM4E 2227/4885ALDH1A1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.